INOZYME PHARMA INC (INZY)
US45790W1080 - Common Stock
We assign a fundamental rating of 1 out of 10 to INZY. INZY was compared to 565 industry peers in the Biotechnology industry. INZY may be in some trouble as it scores bad on both profitability and health. INZY does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year INZY has reported negative net income.
In the past year INZY has reported a negative cash flow from operations.
INZY had negative earnings in each of the past 5 years.
In the past 5 years INZY always reported negative operating cash flow.
1.2 Ratios
INZY has a Return On Assets of -67.31%. This is in the lower half of the industry: INZY underperforms 64.17% of its industry peers.
With a Return On Equity value of -116.56%, INZY perfoms like the industry average, outperforming 41.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.31% | ||
| ROE | -116.56% | ||
| ROIC | N/A |
ROA(3y)-43.15%
ROA(5y)-40.79%
ROE(3y)-53.03%
ROE(5y)-47.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for INZY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, INZY has more shares outstanding
The number of shares outstanding for INZY has been increased compared to 5 years ago.
The debt/assets ratio for INZY is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -3.08, we must say that INZY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.08, INZY perfoms like the industry average, outperforming 48.66% of the companies in the same industry.
A Debt/Equity ratio of 0.51 indicates that INZY is somewhat dependend on debt financing.
INZY's Debt to Equity ratio of 0.51 is on the low side compared to the rest of the industry. INZY is outperformed by 73.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.08 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.68 indicates that INZY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.68, INZY is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
INZY has a Quick Ratio of 7.68. This indicates that INZY is financially healthy and has no problem in meeting its short term obligations.
INZY has a Quick ratio of 7.68. This is in the better half of the industry: INZY outperforms 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.68 | ||
| Quick Ratio | 7.68 |
3. Growth
3.1 Past
The earnings per share for INZY have decreased by -5.48% in the last year.
EPS 1Y (TTM)-5.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, INZY will show a very strong growth in Earnings Per Share. The EPS will grow by 20.17% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.49%
EPS Next 2Y-9.88%
EPS Next 3Y-9.01%
EPS Next 5Y20.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
INZY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INZY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INZY's earnings are expected to decrease with -9.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.88%
EPS Next 3Y-9.01%
5. Dividend
5.1 Amount
No dividends for INZY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INOZYME PHARMA INC
NASDAQ:INZY (11/22/2024, 12:01:58 PM)
2.71
+0.02 (+0.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap174.09M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.31% | ||
| ROE | -116.56% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.68 | ||
| Quick Ratio | 7.68 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-5.48%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-20.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y